296 related articles for article (PubMed ID: 36497275)
1. Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality.
Le BV; Podszywałow-Bartnicka P; Piwocka K; Skorski T
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497275
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
[TBL] [Abstract][Full Text] [Related]
3. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
4. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
Peyraud F; Italiano A
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526888
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of PARP inhibitor resistance and potential overcoming strategies.
Fu X; Li P; Zhou Q; He R; Wang G; Zhu S; Bagheri A; Kupfer G; Pei H; Li J
Genes Dis; 2024 Jan; 11(1):306-320. PubMed ID: 37588193
[TBL] [Abstract][Full Text] [Related]
6. TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment.
Le BV; Podszywalow-Bartnicka P; Maifrede S; Sullivan-Reed K; Nieborowska-Skorska M; Golovine K; Yao JC; Nejati R; Cai KQ; Caruso LB; Swatler J; Dabrowski M; Lian Z; Valent P; Paietta EM; Levine RL; Fernandez HF; Tallman MS; Litzow MR; Huang J; Challen GA; Link D; Tempera I; Wasik MA; Piwocka K; Skorski T
Cell Rep; 2020 Oct; 33(1):108221. PubMed ID: 33027668
[TBL] [Abstract][Full Text] [Related]
7. Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer.
Veneziani AC; Scott C; Wakefield MJ; Tinker AV; Lheureux S
Ther Adv Med Oncol; 2023; 15():17588359231157644. PubMed ID: 36872947
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
9. Recent advancements in PARP inhibitors-based targeted cancer therapy.
Zhou P; Wang J; Mishail D; Wang CY
Precis Clin Med; 2020 Sep; 3(3):187-201. PubMed ID: 32983586
[TBL] [Abstract][Full Text] [Related]
10. PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.
Csizmar CM; Saliba AN; Swisher EM; Kaufmann SH
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34945003
[TBL] [Abstract][Full Text] [Related]
11. PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.
Lee EK; Matulonis UA
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722408
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
Chu YY; Yam C; Yamaguchi H; Hung MC
J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
[TBL] [Abstract][Full Text] [Related]
13. Resistance to PARP-Inhibitors in Cancer Therapy.
Montoni A; Robu M; Pouliot E; Shah GM
Front Pharmacol; 2013; 4():18. PubMed ID: 23450678
[TBL] [Abstract][Full Text] [Related]
14. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
[No Abstract] [Full Text] [Related]
15. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
16. Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations.
Hu J; Liang P; Jin D; Fan R; Xie X; Liu C; Jiang Q; Gao L
Expert Rev Anticancer Ther; 2022 Jul; 22(7):717-723. PubMed ID: 35679134
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
Pham MM; Hinchcliff E; Avila M; Westin SN
Cancer J; 2021 Nov-Dec 01; 27(6):491-500. PubMed ID: 34904812
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology.
Mweempwa A; Wilson MK
Cancer Drug Resist; 2019; 2(3):608-617. PubMed ID: 35582591
[TBL] [Abstract][Full Text] [Related]
19. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
[TBL] [Abstract][Full Text] [Related]
20. Redundancy between nucleases required for homologous recombination promotes PARP inhibitor resistance in the eukaryotic model organism Dictyostelium.
Kolb AL; Gunn AR; Lakin ND
Nucleic Acids Res; 2017 Sep; 45(17):10056-10067. PubMed ID: 28973445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
